These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27978795)

  • 1. Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials.
    Elmaraezy A; Abushouk AI; Saad S; Eltoomy M; Mahmoud O; Hassan HM; Aboelmakarem A; Fotoh AA; Althaher F; Huy NT; Hirayama K
    CNS Neurol Disord Drug Targets; 2017; 16(7):789-799. PubMed ID: 27978795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
    Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
    Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis.
    Li X; Ling L; Li C; Ma Q
    Medicine (Baltimore); 2017 May; 96(18):e6667. PubMed ID: 28471961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.
    Furlan AJ; Eyding D; Albers GW; Al-Rawi Y; Lees KR; Rowley HA; Sachara C; Soehngen M; Warach S; Hacke W;
    Stroke; 2006 May; 37(5):1227-31. PubMed ID: 16574922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke).
    von Kummer R; Mori E; Truelsen T; Jensen JS; Grønning BA; Fiebach JB; Lovblad KO; Pedraza S; Romero JM; Chabriat H; Chang KC; Dávalos A; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A; Albers GW;
    Stroke; 2016 Dec; 47(12):2880-2887. PubMed ID: 27803391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desmoteplase as a potential treatment for cerebral ischaemia.
    Patel R; Ispoglou S; Apostolakis S
    Expert Opin Investig Drugs; 2014 Jun; 23(6):865-73. PubMed ID: 24766516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke.
    Mori E; Minematsu K; Nakagawara J; Hasegawa Y; Nagahiro S; Okada Y; Truelsen T; Lindsten A; Ogawa A; Yamaguchi T;
    Stroke; 2015 Sep; 46(9):2549-54. PubMed ID: 26251244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.
    Hacke W; Furlan AJ; Al-Rawi Y; Davalos A; Fiebach JB; Gruber F; Kaste M; Lipka LJ; Pedraza S; Ringleb PA; Rowley HA; Schneider D; Schwamm LH; Leal JS; Söhngen M; Teal PA; Wilhelm-Ogunbiyi K; Wintermark M; Warach S
    Lancet Neurol; 2009 Feb; 8(2):141-50. PubMed ID: 19097942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
    Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program.
    von Kummer R; Albers GW; Mori E;
    Int J Stroke; 2012 Oct; 7(7):589-96. PubMed ID: 22989394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desmoteplase.
    Paciaroni M; Medeiros E; Bogousslavsky J
    Expert Opin Biol Ther; 2009 Jun; 9(6):773-8. PubMed ID: 19456211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
    Kumar G; Uhrig D; Fowler S; DeLaney MC; Alexandrov AV
    CNS Drugs; 2015 Aug; 29(8):659-67. PubMed ID: 26251162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase.
    Fiebach JB; Al-Rawi Y; Wintermark M; Furlan AJ; Rowley HA; Lindstén A; Smyej J; Eng P; Warach S; Pedraza S
    Stroke; 2012 Jun; 43(6):1561-6. PubMed ID: 22474060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic stroke onset.
    Otwell JL; Phillippe HM; Dixon KS
    Am J Health Syst Pharm; 2010 Jul; 67(13):1070-4. PubMed ID: 20554592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravenous thrombolysis in ischemic stroke: Therapeutic perspectives].
    Paris C; Derex L
    Rev Neurol (Paris); 2015 Dec; 171(12):866-75. PubMed ID: 26563662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desmoteplase for Acute Ischemic Stroke within 3 to 9 Hours after Symptom Onset: Evidence from Randomized Controlled Trials.
    Shi L; Liang F; Li Y; Shao A; Zhou K; Yu J; Zhang J
    Sci Rep; 2016 Sep; 6():33989. PubMed ID: 27671010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refinement of the magnetic resonance diffusion-perfusion mismatch concept for thrombolytic patient selection: insights from the desmoteplase in acute stroke trials.
    Warach S; Al-Rawi Y; Furlan AJ; Fiebach JB; Wintermark M; Lindstén A; Smyej J; Bharucha DB; Pedraza S; Rowley HA
    Stroke; 2012 Sep; 43(9):2313-8. PubMed ID: 22738918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desmoteplase in the treatment of acute ischemic stroke.
    Dafer RM; Biller J
    Expert Rev Neurother; 2007 Apr; 7(4):333-7. PubMed ID: 17425487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin Treatment in Patients with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yao X; Wang D; Li H; Shen H; Shu Z; Chen G
    Curr Drug Deliv; 2017 Sep; 14(6):853-860. PubMed ID: 27549753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of clinical outcomes of intravenous recombinant tissue plasminogen activator for acute ischemic stroke: within 3 hours versus 3-4.5 hours.
    Li BH; Ding X; Yin YW; Liu Y; Gao CY; Zhang LL; Li JC
    Curr Med Res Opin; 2013 Sep; 29(9):1105-14. PubMed ID: 23790245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.